Arguably the best medical imaging tool in common use today, Magnetic Resonance Imaging (MRI) enables a clinician to “see” in detail the internal organs of a patient non-invasively while thermal coagulation therapy has proven utility in multiple medical treatment applications.

 

When combining the two methodologies, the opportunity exists for an optimal and vastly superior clinical outcome.
Profound has developed a novel MRI-compatible ultrasound applicator to deliver controlled thermal therapy to the regions of the prostate gland via a trans-urethral approach. Featuring intelligent closed-loop control via real-time thermal imaging, the Profound system offers unparalleled accuracy.

The system has been extensively tested and delivered consistent and predictable proof-of-concept results in mathematical, gel, pre-clinical models and the technology is approved for Safety and Feasibility Clinical trials in North America and Europe, currently enrolling patients. 

 

System Features 

• Safety & compatibility within an MRI suite
• Accurate location of the trans-urethral ultrasound applicator in the prostate
• Customisable 3D treatment planning options through proprietary software
• Precise heating control through unique array geometries and frequencies
• Whole or segmented treatments relative to disease progression and location
• Single treatment, within MR scanner, on outpatient basis
• Real-time thermometry for active monitoring and surveillance
• Control around critical organs such as nerve bundles, rectum & bladder

Jean-François Pariseau joined BDC Venture Capital in July 2001. He has over 17 years of investment and entrepreneurial experience in the life sciences sector. He has invested and managed more than $200 million in biopharmaceutical and medical device companies in North America. Jean-Francois’ experience includes transactions in private and in public companies, IPOs, M&A and fund investments. Prior to this, he was CEO of a consulting company specializing in regulatory affairs as well as VP, R&D for a pharmaceutical-product distribution company, both of which he founded. Mr. Pariseau holds a Bachelor of Science in Biotechnology from Université de Sherbrooke, a Master of Science in Biomedical Sciences from Université de Montréal, and an MBA from HEC-Montréal. He currently sits on the Board of Directors of AngioChem Inc., Osprey Pharmaceuticals USA, Profound Medical Inc. and BioQuébec.

 

Damian Lamb, Genesys Capital Partners Co-Founder and Managing Director
Mr. Lamb is co-Founder and Managing Director of Genesys Capital. He brings a unique experience base, blending skills in both the commercial and technical side of biotechnology. Since co-founding Genesys Capital in 2000, Mr. Lamb has been instrumental in raising over $200 million in venture capital funds, and has been involved in deploying over $90 million in 18 investments. He currently serves on the Board of Affinium Pharmaceuticals Inc.. He has served on the Board of Ionalytics Corporation (recently sold to Thermo Electron Corp.), Millenium Biologix and was Chairman of the Board of DELEX Therapeutics Inc. when it was sold to YM BioSciences. Mr. Lamb works closely with Genesys investee companies to strategically position the companies to build value for shareholders.

Steven Plymale, CEO, Profound Medical Inc.
Mr. Plymale has over two decades of senior management experience in the medical device industry and was most recently the Vice President and General Manager of Xltek, a division of Natus Medical Incorporated. Xltek, formerly a public company, was acquired by Natus Medical in November 2007, and designs, manufactures and sells a broad portfolio of diagnostic monitoring devices for Neurology. Prior to this appointment Mr. Plymale served in various senior management roles within several medical device companies (such as ISG Technologices,/Cedara Software, CryoCath Technology, Claron Technology and The Bluehaven Consulting group). Mr. Plymale brings a unique blend of management skills and experience focusing on Operations, Quality & Regulatory Affairs and Strategic Planning.

William E. Curran

Mr. Curran has extensive experience in operations, finance and executive management. He was formerly President and Chief Executive Officer of Philips Electronics North America. He served in diverse functional and senior management positions during his career with Philips, including as Chief Operating Officer of Philips Medical Systems North America. Mr. Curran currently serves on the Board of 3D Systems (NYSE: DDD) and is Chairman of the Audit Committee and a member of the Executive Committee. He was non-executive Chairman and a Director of Resonant Medical before it was sold to Elekta A.B. in 2010.He has previously served as a director for companies in the medical, electronics, and software industries.

Eric A. Klein, MD, Chair of the Glickman Urological and Kidney Institute and professor of Surgery in the Lerner College of Medicine of the Cleveland Clinic
Dr. Klein’s clinical and research interests cover all of urologic oncology and particularly clinical trials for localized and locally advanced prostate cancer. He serves as the Chairman of the Localized Prostate Cancer Committee of the Southwest Oncology Group and is the National Study Coordinator for the NCIsponsored Selenium and Vitamin E Cancer Prevention Trial (SELECT). Dr. Klein has contributed more than 300 papers to the scientific literature, authored or edited 7 books on urologic malignancies, and serves as the Editor-in-Chief of Urology.

Laurence Klotz, MD, Chief of Urology, Sunnybrook Health Sciences, Toronto
Dr Klotz is Chief of Urology at Sunnybrook Health Sciences Centre, and is a globally-renowned clinician in the area of Uro-oncology. He is also Chairman of the World Uro-Oncology Federation. Additionally, Dr. Klotz is the Founding Editor-in-Chief of the Canadian Journal of Urology. Dr. Klotz obtained his medical degree from the University of Toronto and completed his residency at the University of Toronto Gallie Program in Surgery. Dr. Klotz continued his postgraduate studies with a special fellowship at Memorial Sloan Kettering Cancer Centre in New York in uro-oncology and tumour biology. Dr. Klotz is a widely published uro-oncologist who serves on the board or heads many medical/scientific organizations and committees.

Michael Marberger, MD, Chairman, Dept of Urology, Vienna
Dr. Marberger has served as Professor and Chairman of the Department of Urology of the University of Vienna Medical School since 1990. During his illustrious career he has published over 500 articles in peer reviewed journals and edited 5 text books of Urology. Most recently he was 2011 EAU Congress President. He is also currently Editor-in-Chief of Current Opinion in Urology and on the Editorial Boards of several major urological journals. He serves/served as officer on the boards of major international professional societies such as the EAU, the SIU and the Endourology Society. He received numerous awards, among them the Dr.h.c. of the Semmelweis University Budapest, the Honorary Fellowship of the Royal College of Surgeons of Edinburgh, the SIU – Yamanouchi Lifetime Achievement Award, the St. Paul’s Medal of the British Association of Urological Surgeons, the Certificate of Achievement Award of the American Association of Urology.

Mukesh Harisinghani, MD, Associate Professor; Harvard Medical School; Head, Abdominal MRI, Massachusetts General Hospital; Section Editor, GU Imaging, American Journal of Roentgenology
Dr. Harisinghani heads the Abdominal MRI at the Massachusetts General Hospital and is globally renowned in the field of genitourinary imaging. He is GU section editor of the American Journal of Roentgenology and is a member of the Radiological Society of America.